Search the Newsreel

Earnings Flash (ADN.TO) Acadian Timber Corp. Reports Q2 Revenue C$14.6M

ACADIA PHARMACEUTICALS INC SEC Filing (Aug 5, 2026)

This article reports on an SEC Form 144 filing by ACADIA PHARMACEUTICALS INC (ACAD) on August 5, 2026, indicating a proposed sale of 5849 shares of common stock acquired through a stock option exercise, with an aggregate market value of $158,800.35, to be sold …

ACADIA Pharmaceuticals Inc. Revenue Breakdown – BMV:ACAD

ACADIA Pharmaceuticals Inc. (BMV:ACAD) generated 19.32 billion MXN in revenue last year, primarily from its Innovative Medicines segment. The United States was the largest contributor to this revenue, accounting for the entire 19.32 billion MXN. This revenue figure is a slight decrease from the …

RBC Capital raises Acadia Pharmaceuticals price target on strong Daybue sales

RBC Capital has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $37 from $36, maintaining an Outperform rating, due to better-than-expected Daybue sales. The company's strong performance, including $125 million in Daybue sales and solid Nuplazid performance, led to an increase in …

Acadia Pharmaceuticals stock hits 52-week high at 28.4 USD

Acadia Pharmaceuticals Inc. (ACAD) stock reached a new 52-week high of $28.35, currently trading at $28.92, reflecting a 19.75% increase over the past year. InvestingPro analysis suggests the stock is undervalued, boasting an attractive P/E ratio of 12.23 and a low PEG ratio of …

ACADIA Pharmaceuticals Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-08-05

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $0.18, beating estimates by $0.14, and revenue of $307.96 million, a 16.40% year-over-year increase, surpassing expectations by $12.44 million. This presentation provides investors …

Acadia Realty Trust $AKR Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in Acadia Realty Trust (NYSE:AKR) by 3.5% in the first quarter, now owning approximately 1.4% of the company's stock. Despite missing earnings estimates in its latest quarterly report, Acadia Realty Trust maintains a "Moderate Buy" consensus rating …

RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating

RBC Capital has increased its price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) to $37 from $36, while reiterating an Outperform rating. This adjustment follows ACADIA Pharmaceuticals' Q2 Daybue sales exceeding expectations due to Stix Formulation uptake, which supports an improved outlook for the company.

Earnings call transcript: ACADIA tops Q2 2026 revenue forecast as shares rise

ACADIA Pharmaceuticals reported strong Q2 2026 results, with revenue reaching $308 million, surpassing analyst forecasts. The growth was primarily driven by robust sales of DAYBUE for Rett syndrome and NUPLAZID for Parkinson’s disease psychosis, leading the company to raise its 2026 DAYBUE sales guidance …

Acadian Asset Management (NYSE:AAMI) Hits New 12-Month High - Should You Buy?

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High After Strong Earnings

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadian Timber Q2 2026 Earnings Call Transcript

Hospital Chains Stocks Q2 Earnings: Tenet Healthcare (NYSE:THC) Best of the Bunch

ACADIA Pharmaceuticals (ACAD) Stock Looks Cheap On Earnings Yet Weak On Recent Returns

ACADIA Pharmaceuticals (ACAD) stock has seen a 38.5% gain over five years but has delivered softer returns recently. Despite this, Simply Wall St's analysis suggests the stock appears relatively cheap, trading at 11.7x earnings, well below the biotech sector average, and passing multiple valuation …

Earnings Flash (ACAD) Acadia Pharmaceuticals Inc. Reports Q2 Revenue $308.0M, vs. FactSet Est of $295.5M

Acadia Pharmaceuticals Inc. (ACAD) reported its Q2 revenue at $308.0 million, surpassing the FactSet estimate of $295.5 million. The company's stock symbol is ACAD, and it operates in the Biotechnology & Medical Research sector. This positive financial performance was also accompanied by an increase …

BofA Securities Maintains Acadia Realty Trust(AKR.US) With Buy Rating

BofA Securities has reiterated its Buy rating on Acadia Realty Trust (AKR.US). The article does not provide further details regarding the reasoning behind this rating.

Acadia Healthcare Company Stock Short Interest Falls to 37.33%

This article reports on the significant decrease in short interest for Acadia Healthcare Company (ACHC) stock, which fell by 37.33% in the second half of July. Despite this reduction, a substantial percentage of the company's shares are still held short, indicating continued investor sentiment …

ETFs Investing in ACADIA Pharmaceuticals Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold stocks of ACADIA Pharmaceuticals Inc. (ACAD). The list is sorted by market value and includes various details for each ETF, such as issuer, management style, focus, expense ratio, assets under management, …

What Academy Sports and Outdoors (ASO)'s New Retail Media Network Means For Shareholders

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

121,500 Shares in Acadia Healthcare Company, Inc. $ACHC Acquired by Militia Capital Management LLC

Militia Capital Management LLC acquired 121,500 shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) valued at approximately $2.84 million in the first quarter, representing about 0.13% of the company. Other institutional investors also adjusted their holdings in ACHC, which reported quarterly EPS of $0.38 against …

AKR Maintained by Citigroup -- Price Target Raised to $26.00

Citigroup has maintained a Buy rating for Acadia Realty Trust (AKR) and raised its price target from $24.00 to $26.00, reflecting optimism despite the stock being 22.8% overvalued according to GuruFocus. The company shows strong profitability but limited growth potential and recent insider selling, …

All You Need to Know About Academy Sports and Outdoors (ASO) Rating Upgrade to Buy

Academy Sports and Outdoors, Inc. (ASO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces …

ASO vs. AS: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Leisure and Recreation Products sector might want to consider either Academy Sports and Outdoors, Inc. (ASO) or Amer Sports, Inc. (AS). But which of these two stocks offers value investors a better bang for their buck right now? …

Citi Maintains Acadia Realty Trust(AKR.US) With Buy Rating, Raises Target Price to $26

Citi has reiterated its Buy rating on Acadia Realty Trust (AKR.US) and increased its target price for the stock to $26. This adjustment suggests a positive outlook from Citi on the company's future performance.

Acadian Asset Management Inc. (NYSE:AAMI) Given Consensus Recommendation of "Moderate Buy" by Analysts

Are Investors Undervaluing Academy Sports and Outdoors (ASO) Right Now?

The article suggests that Academy Sports and Outdoors (ASO) and OneWater Marine (ONEW) may be undervalued by the market, based on Zacks' value investing criteria. ASO currently holds a Zacks Rank #2 (Buy) and an "A" grade for Value, with favorable P/E, P/B, and …

Sei Investments Co. Raises Stake in Acadia Healthcare Company, Inc. $ACHC

Sei Investments Co. increased its stake in Acadia Healthcare Company, Inc. by 39% in the first quarter, now holding 316,398 shares valued at $7.4 million. Despite mixed analyst ratings, the company beat its quarterly earnings and revenue expectations, reporting $0.38 EPS and $865.84 million …

ETFs Investing in Acadia Healthcare Company, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Acadia Healthcare Company, Inc. It provides a detailed table including each ETF's market value, weight of Acadia Healthcare stock, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and …

Acadian Asset Management Inc. $AAMI Stock Position Lowered by Healthcare of Ontario Pension Plan Trust Fund

Acadia Realty Trust (AKR) Lifts Earnings View As Fair Value Questions Return

Acadia Realty Trust (AKR) has increased its 2026 net earnings guidance to $0.40-$0.41 per share after a strong second quarter, leading to positive stock momentum. Despite recent gains, the stock remains below analyst targets and intrinsic estimates, with a narrative fair value of $23.50 …

ACADIA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Ndu Adora

This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Director Ndu Adora at ACADIA Pharmaceuticals. It indicates a change in ownership of securities for the named individual. The document itself is not provided, only its existence is noted.

Why Acadia Healthcare (ACHC) Is Down 17.3% After Raising 2026 Revenue Guidance Amid Earnings Drop

Acadia Healthcare (ACHC) shares dropped 17.3% despite the company raising its 2026 revenue guidance to US$3.40–US$3.45 billion. This follows a second quarter where sales were flat and net income sharply declined to US$10.93 million. The market reaction indicates that ongoing legal and regulatory risks …

Acadia Realty Trust (NYSE:AKR) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Acadia Realty Trust (NYSE:AKR) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy." The downgrade follows Acadia reporting quarterly EPS of $0.05, missing estimates, though revenue exceeded expectations. An executive vice president also sold a significant …

Acadian Asset Management Inc. $AAMI Shares Sold by Arrowstreet Capital Limited Partnership